Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to $15.0 million.

  • NewAmsterdam Pharma's Share-based Compensation rose 8771.89% to $15.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year increase of 8145.32%. This contributed to the annual value of $33.6 million for FY2024, which is 3681.83% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma's Share-based Compensation stood at $15.0 million, which was up 8771.89% from $15.2 million recorded in Q2 2025.
  • NewAmsterdam Pharma's Share-based Compensation's 5-year high stood at $15.2 million during Q1 2025, with a 5-year trough of $5.4 million in Q3 2023.
  • For the 3-year period, NewAmsterdam Pharma's Share-based Compensation averaged around $9.4 million, with its median value being $8.0 million (2024).
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 396.53% in 2024, then surged by 9213.19% in 2025.
  • Over the past 3 years, NewAmsterdam Pharma's Share-based Compensation (Quarter) stood at $6.0 million in 2023, then soared by 56.76% to $9.4 million in 2024, then surged by 59.43% to $15.0 million in 2025.
  • Its Share-based Compensation stands at $15.0 million for Q3 2025, versus $15.2 million for Q2 2025 and $15.2 million for Q1 2025.